▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #120 by analyst upside · 2026-11-13
CRBU
Caribou Biosciences, Inc.
Healthcare · Market Cap $41M · P/E 0x
ANALYST PRICE TARGET
+1215.1%
implied upside to consensus target
Current Price $0.38
Consensus Target $5.0
Bull Target $13.0
Bear Target $1.0
Analysts Covering 3
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
1
Hold
2
Sell
0
52-Week Low $0.36
52-Week High $2.49
YTD Return -76.1%
FUNDAMENTALS
Market Cap $41M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.03
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $9M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.36
52-Week High $2.49
Current Price $0.38
Bear Target $1.0
Bull Target $13.0
● Now $0.38 ● Target $5.0
TRADING DATA
Avg Volume 2.7M
YTD Return -76.1%
Analyst Count 3
Consensus Hold
Upside to Target +1215.1%
Last Updated 2026-11-13

ANALYST SUMMARY

Caribou Biosciences, Inc. (CRBU) is currently trading at $0.38 with a Wall Street consensus price target of $5.0, implying potential upside of 1215.1% over the next 12 months. 3 analysts currently cover CRBU, with a consensus rating of Hold - 33% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $13.0, while the most cautious has a target of $1.0.

CRBU operates in the Healthcare sector with a market capitalisation of $41M. The stock is down 76.1% year-to-date and is currently trading near the lower end of its 52-week range of $0.36 – $2.49.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CRBU, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. ↓ Downgrade
Buy → Neutral 2026-10-08 31% win rate (48 calls)
Brookline Capital ↓ Downgrade
Buy → Hold 2026-10-07 20% win rate (5 calls)
RBC Capital ↓ Downgrade
Outperform → Sector Perform 2026-10-07 Building track record
Leerink Partners ↓ Downgrade
Outperform → Market Perform 2026-10-07 29% win rate (7 calls)
B of A Securities - Reiterated
Buy → Buy 2026-08-14 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-05-11 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-04-07 31% win rate (48 calls)
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-03-09 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
13
out of 100
Coverage depth
11/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →